Ekso Bionics Holdings Inc (NASDAQ:EKSO) shares traded up 9.1% during trading on Friday . The company traded as high as $2.30 and last traded at $2.27. 812,732 shares changed hands during mid-day trading, an increase of 33% from the average session volume of 612,877 shares. The stock had previously closed at $2.08.

A number of research analysts have commented on the stock. Zacks Investment Research cut shares of Ekso Bionics from a “buy” rating to a “sell” rating in a research report on Monday, September 17th. ValuEngine raised shares of Ekso Bionics from a “hold” rating to a “buy” rating in a research report on Thursday, July 12th.

The company has a quick ratio of 1.92, a current ratio of 2.17 and a debt-to-equity ratio of 0.49.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Tuesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 327.12% and a negative return on equity of 169.75%. The company had revenue of $2.97 million during the quarter, compared to analyst estimates of $3.03 million. equities research analysts forecast that Ekso Bionics Holdings Inc will post -0.45 earnings per share for the current fiscal year.

Ekso Bionics Company Profile (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

See Also: Penny Stocks, Risk and Reward Factors

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.